神経筋疾患治療法の世界市場2019-2023

◆英語タイトル:Neuromuscular Disease Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023
◆商品コード:IRTNTR31938
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年8月28日
◆ページ数:134
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア太平洋、ヨーロッパ、北米、その他
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥262,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥315,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、神経筋疾患治療法の世界市場について調べ、神経筋疾患治療法の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、神経筋疾患治療法の市場規模をセグメンテーション別(種類別(生物製剤、小分子)、)と地域別(グローバル、アジア太平洋、ヨーロッパ、北米、その他)に分けて算出しました。Technavio社は神経筋疾患治療法の世界市場規模が2019-2023期間中に年平均14%成長すると予測しています。
・サマリー
・レポートの範囲
・神経筋疾患治療法の市場状況
・神経筋疾患治療法の市場規模
・神経筋疾患治療法の市場予測
・神経筋疾患治療法の世界環境:ファイブフォース分析
・市場セグメンテーション:種類別(生物製剤、小分子)
・神経筋疾患治療法の顧客状況
・主要地域別市場規模:グローバル、アジア太平洋、ヨーロッパ、北米、その他
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Neuromuscular Diseases Therapeutics Market: About this market
Technavio’s neuromuscular diseases therapeutics market analysis considers sales from both biologics and small molecules. Our analysis also considers the sales of neuromuscular diseases therapeutics in Asia, Europe, North America, and ROW. In 2018, the biologics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as increasing number of special drug designation and clinical efficacy of late-stage pipeline drugs will play a significant role in the biologics segment to maintain its market position. Also, our global neuromuscular diseases therapeutics market report looks at factors such as novel approvals, newborn screening tests, and huge unmet need for neuromuscular diseases therapeutics. However, economic burden on patients, stringent regulatory guidelines, and fast progressive nature of neuromuscular diseases may hamper the growth of the neuromuscular diseases therapeutics industry over the forecast period.

Global Neuromuscular Diseases Therapeutics Market: Overview

Novel approvals
Owing to the rapidly progressive nature of the disease, treatments using drugs are not effective and do not stop the disease progression. This leads the vendors to conduct researches on the development of gene therapies and antisense therapies that can stop the progression of the disease and increase the life expectancy of the patients. Thus, the increasing number of drug approvals will lead to the expansion of the global neuromuscular diseases’ therapeutics market at a CAGR of over 14% during the forecast period.

Technological Advances
One of the major factors that are expected to contribute significantly to the R&D of novel therapeutics for neuromuscular diseases is increasing technological advances. The lack of efficacy and non-disease-modifying drugs for the treatment are leading the vendors to focus on identifying the benefits of regenerative therapies as a potential treatment option. The advent of next generation genetic sequencing technology focuses on sequencing human genome while significantly reducing the associated costs. This results in the market witnessing advance sin the identification of mutated genes that cause neuromuscular diseases. This development is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global neuromuscular diseases therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape
With the presence of a few major players, the global neuromuscular diseases therapeutics market is highly concentrated. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading neuromuscular diseases therapeutics manufacturers, that include Biogen Inc., Novartis AG, PTC Therapeutics Inc., Sanofi, Sarepta Therapeutics Inc.

Also, the neuromuscular diseases therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: PIPELINE
PART 07: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Biologics – Market size and forecast 2018-2023
• Small molecules – Market size and forecast 2018-2023
• Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
• Technological advances
• Inherited nature of neuromuscular diseases
• Increasing research funding
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Biogen Inc.
• Novartis AG
• PTC Therapeutics Inc.
• Sanofi
• Sarepta Therapeutics Inc.
PART 15: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 16: EXPLORE TECHNAVIO

Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Global neuromuscular diseases therapeutics market pipeline: Overview
Exhibit 19: Global neuromuscular diseases therapeutics market pipeline: Snapshot
Exhibit 20: Type – Market share 2018-2023 (%)
Exhibit 21: Comparison by type
Exhibit 22: Biologics – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Biologics – Year-over-year growth 2019-2023 (%)
Exhibit 24: Small molecules – Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Small molecules – Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by type
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America – Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Biogen Inc. – Vendor overview
Exhibit 51: Biogen Inc. – Business segments
Exhibit 52: Biogen Inc. – Organizational developments
Exhibit 53: Biogen Inc. – Geographic focus
Exhibit 54: Biogen Inc. – Key offerings
Exhibit 55: Biogen Inc. – Key customers
Exhibit 56: Novartis AG – Vendor overview
Exhibit 57: Novartis AG – Business segments
Exhibit 58: Novartis AG – Organizational developments
Exhibit 59: Novartis AG – Geographic focus
Exhibit 60: Novartis AG – Segment focus
Exhibit 61: Novartis AG – Key offerings
Exhibit 62: Novartis AG – Key customers
Exhibit 63: PTC Therapeutics Inc. – Vendor overview
Exhibit 64: PTC Therapeutics Inc. – Business segments
Exhibit 65: PTC Therapeutics Inc. – Organizational developments
Exhibit 66: PTC Therapeutics Inc. – Key offerings
Exhibit 67: PTC Therapeutics Inc. – Key customers
Exhibit 68: Sanofi – Vendor overview
Exhibit 69: Sanofi – Business segments
Exhibit 70: Sanofi – Organizational developments
Exhibit 71: Sanofi – Geographic focus
Exhibit 72: Sanofi – Segment focus
Exhibit 73: Sanofi – Key offerings
Exhibit 74: Sanofi – Key customers
Exhibit 75: Sarepta Therapeutics Inc. – Vendor overview
Exhibit 76: Sarepta Therapeutics Inc. – Business segments
Exhibit 77: Sarepta Therapeutics Inc. – Organizational developments
Exhibit 78: Sarepta Therapeutics Inc. – Geographic focus
Exhibit 79: Sarepta Therapeutics Inc. – Key offerings
Exhibit 80: Sarepta Therapeutics Inc. – Key customers
Exhibit 81: Validation techniques employed for market sizing
Exhibit 82: Definition of market positioning of vendors



【掲載企業】

Biogen Inc., Novartis AG, PTC Therapeutics Inc., Sanofi, and Sarepta Therapeutics Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[神経筋疾患治療法の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆